Calviri's groundbreaking canine cancer vaccine, led by Stephen Johnston, PhD, shows promise in preventing eight types of canine cancers, reducing tumors and chronic diseases in trials. Pending USDA approval, it aims for affordability, signaling a major leap in both canine and human health.

Minneapolis, United States - February 9, 2024 —

In a groundbreaking development for veterinary medicine, Calviri, Inc., under the visionary leadership of CEO Stephen Johnston, PhD, has announced a major breakthrough in canine health with the introduction of a novel cancer vaccine. This innovative vaccine, currently in advanced stages of clinical trials, has shown remarkable promise in preventing eight types of cancer in dogs, marking a pivotal moment in the fight against the leading cause of death in senior canines.

Developed through years of meticulous research and leveraging cutting-edge DNA technology, the vaccine targets specific neoantigens produced by tumors, teaching the immune system to recognize and combat cancer cells effectively. Johnston's team has meticulously identified 30 specific neoantigens from a pool of 1.4 million, creating a vaccine that prepares the dog's immune system to fight cancer as soon as it arises, much like it would against infectious diseases.

Preliminary results from the ongoing Vaccination Against Canine Cancer Study are encouraging, demonstrating a significant reduction in tumor development in about 65 percent of vaccinated dogs. Notably, the vaccine also inadvertently led to a more than 50 percent reduction in the incidence of non-cancer chronic diseases, such as arthritis and metabolic diseases, attributed to an immune response against senescent cells, often the precursors of chronic conditions.

While the vaccine has shown a substantial impact on several cancer types, including mast cell tumors and adrenal tumors, challenges remain, particularly in preventing hemangiosarcoma. However, Johnston is optimistic, citing adjustments in the vaccine's components for future trials to address these issues. Importantly, no safety concerns have been raised during the trials, underscoring the vaccine's potential as a safe preventive measure against canine cancer.

Calviri is committed to making this vaccine accessible and affordable, positioning it as a game-changer in veterinary care and a beacon of hope for pet owners worldwide. Pending USDA approval, the vaccine's launch will not only represent a significant advance in canine health but also holds promise for cancer prevention strategies in humans, reflecting Johnston's vision of a cancer-free future for all.

As Calviri prepares for the next phase of trials and navigates the regulatory approval process, the veterinary community and pet owners alike await with bated breath, hopeful for a future where cancer is no longer a death sentence for beloved canine companions.

Source:

https://www.avma.org/javma-news/2011-06-15/study-examines-causes-death-dogs

https://med.umn.edu/news/defining-zombie-cells

Contact Info:
Name: Mark S
Email: Send Email
Organization: hoehlenwolf
Address: 3732 Sycamore Fork Road, Minneapolis, MN 55402, United States
Website: https://hoehlenwolf.wordpress.com/

Source: PressCable

Release ID: 89121156

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at error@releasecontact.com. Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.